Table 1.
Proportion of participants eligible for statin therapy according to changes in ESC/EAS clinical guidelines and associated cost implications
| Year of clinical guideline | Proportion eligible for statins, % (SE) | Cost, € | 95% CI |
|---|---|---|---|
| 1987 | 7.95 (0.33) | 13 902 610 | 12 668 710 to 15 045 833 |
| 1994 | 9.68 (0.44) | 16 924 364 | 15 364 264 to 18 456 889 |
| 1998 | 20.46 (0.60) | 35 767 583 | 33 583 491 to 37 922 496 |
| 2004 | 33.33 (0.70) | 58 256 655 | 55 808 914 to 60 866 411 |
| 2007 | 41.14 (0.73) | 71 918 939 | 69 140 111 to 74 850 412 |
| 2012 | 62.33 (0.72) | 108 959 843 | 106 127 604 to 112 017 290 |
| 2016 | 61.27 (0.73) | 107 100 599 | 104 314 514 to 110 061 679 |
ESC/EAS = European Society of Cardiology/European Atherosclerosis Society. SE = standard error.